11 reports

  • CYCLACEL PHARMACEUTICALS INC, PHARMACEUTICALS & HEALTHCARE, DEAL DETAILS
  • Cyclacel Pharmaceuticals Inc, Subsidiaries

Summary Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies.The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, CDK inhibitor...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Cyclacel Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals Inc - Opportunities
  • Cyclacel Pharmaceuticals Inc - Threats

Cyclacel Pharmaceuticals Inc (CYCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities...

  • Healthcare
  • Pharmaceutical
  • United States
  • Company Financials
  • Cyclacel Pharmaceuticals, Inc.
  • Comparative Business Analysis: Cyclacel Pharmaceuticals, Inc.
  • Fixed Charges Coverage: Cyclacel Pharmaceuticals, Inc.

A textual analysis of the financial results for Cyclacel Pharmaceuticals, Inc. compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description of the company, including...

  • Pharmaceutical
  • United States
  • Company Financials
  • Cyclacel Pharmaceuticals, Inc.
  • AML - Late-Stage Pipeline, 2015
  • Sapacitabine SWOT Analysis

Guadecitabine is presently in Phase III development in the US and the EU (Astex Pharmaceuticals, NCT##; ASTRAL-##) and a Phase I trial is being conducted by Otsuka Pharmaceuticals in Japan.

  • Pharmaceutical
  • United States
  • World
  • Demand
  • Cyclacel Pharmaceuticals, Inc.
  • Valuation multiples (Cyclacel Pharmaceuticals, Inc.)
  • Valuation multiples (Cyclacel Pharmaceuticals, Inc.)

Summary Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. This report includes Cyclacel Pharmaceuticals, Inc.'s contact information...

  • Pharmaceutical
  • United States
  • Corporate Finance
  • Cyclacel Pharmaceuticals, Inc.
  • Astex Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2018 Summary Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 11 molecules. Out...

  • Cancer
  • Hospital
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.
  • Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H1 2018 Summary Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 10 molecules. Out...

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals Inc
  • Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the recently published report ’Cyclin Dependent Like Kinase 5 - Pipeline Review, H2 2017’; Cyclin...

  • Cancer
  • Pathology
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline...

  • Cancer
  • Pathology
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.

Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor...

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016

Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) - Pipeline Review, H1 2016’, provides in depth analysis on Cyclin-Dependent...

  • Cancer
  • Pathology
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.